Search
Now showing items 2101-2110 of 2294
Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells.
(IMPACT JOURNALS LLC, 2017-10-27)
The HOX genes encode a family of transcription factors that have key roles in both development and malignancy. Disrupting the interaction between HOX proteins and their binding partner, PBX, has been shown to cause apoptotic ...
Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository.
(BMC, 2017-11-23)
BACKGROUND: Randomised clinical trials (RCTs) are the gold standard for evaluating new cancer treatments. They are, however, expensive to conduct, particularly where long-term follow-up of participants is required. Tracking ...
Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials.
(TAYLOR & FRANCIS LTD, 2018-01-01)
BACKGROUND: The study of the intrinsic molecular subtypes of breast cancer has revealed differences among them in terms of prognosis and response to chemotherapy and endocrine therapy. However, the ability of intrinsic ...
Meeting report from the joint IARC-NCI international cancer seminar series: a focus on colorectal cancer.
(ELSEVIER, 2019-04-01)
Despite significant progress in our understanding of the etiology, biology and genetics of colorectal cancer, as well as important clinical advances, it remains the third most frequently diagnosed cancer worldwide and is ...
A novel PAX5 rearrangement in TCF3-PBX1 acute lymphoblastic leukemia: a case report.
(BMC, 2018-12-18)
BACKGROUND: Chromosome translocations are a hallmark of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Additional genomic aberrations are also crucial in both BCP-ALL leukemogenesis and treatment management. ...
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
(ELSEVIER SCI LTD, 2018-03-01)
BACKGROUND: Most metastatic melanoma patients treated with BRAF inhibitors (BRAFi) ± MEK inhibitors (MEKi) eventually progress on treatment. Along with acquired resistance due to genetic changes, epigenetic mechanisms that ...
IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia.
(ELSEVIER SCIENCE INC, 2019-05-01)
IKZF1 deletion (ΔIKZF1) is an important predictor of relapse in both childhood and adult B-cell precursor acute lymphoblastic leukemia (B-ALL). Previously, we revealed that COBL is a hotspot for breakpoints in leukemia and ...
2018 ESMO Sarcoma and GIST Symposium: 'take-home messages' in soft tissue sarcoma.
(ELSEVIER, 2018-05-01)
The 7th edition of the 'ESMO Sarcoma and GIST Symposium' was held in Milan in February 2018. For the first time, the Symposium brought together representatives from the European Reference Network on rare adult solid cancer ...
Ending 40 years of silence: Rationale for a new staging system for soft tissue sarcoma of the head and neck.
(ELSEVIER IRELAND LTD, 2019-02-01)
The tumor, node, metastases (TNM) anatomic staging system plays a pivotal role in cancer care, research, and cancer control activities. Since the first edition of the American Joint Committee on Cancer TNM staging ...
How we treat neurological toxicity from immune checkpoint inhibitors.
(ELSEVIER, 2019-07-01)
Neurological adverse events from immune checkpoint inhibition are increasingly recognised, especially with combination anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) and anti-programmed death receptor 1 (anti-PD-1) therapies. ...